Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | PARP1 | P09874 | 1/20 | 0.68 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.59 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.59 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Procodazole SCHEMBL29404024 | 1.00 | CHRM1 (1.00) | CHRM1KDM4EPARP1PARP2CYP1A2 | |
| Procodazole SCHEMBL349966 | 1.00 | CHRM1 (1.00) | CHRM1KDM4EPARP1PARP2CYP1A2 | |
| Procodazole SCHEMBL5413283 | 0.95 | CHRM1 (0.91) | CHRM1KDM4EPARP1PARP2CYP1A2 | |
| SCHEMBL2017763 | 0.90 | CHRM1 (0.82) | CHRM1KDM4ECYP1A2CYP2C9MAPT | |
| SCHEMBL7433457 | 0.89 | CHRM1 (0.80) | CHRM1KDM4ECYP1A2CYP2C9MAPT | |
| SCHEMBL14565997 | 0.88 | CHRM1 (0.78) | CHRM1KDM4ECYP1A2CYP2C9MAPT | |
| SCHEMBL12999426 | 0.86 | GAA (0.75) | CHRM1KDM4ECYP1A2CYP2C9MAPT | |
| SCHEMBL4573158 | 0.85 | CHRM1 (0.74) | CHRM1KDM4ECYP1A2CYP2C9MAPT | |
| SCHEMBL19368796 | 0.85 | CHRM1 (0.74) | CHRM1KDM4ECYP1A2CYP2C9MAPT | |
| SCHEMBL5717769 | 0.85 | CHRM1 (0.74) | CHRM1KDM4ECYP1A2CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703653-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | University Of Virginia Patent Foundation (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200268665-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-8968702-B2 | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses | DUKE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140249097-A1 | Inhibition of HIF-1 activation for Anti-Tumor and Anti-Inflammatory responses | DUKE UNIVERSITY | 2014-09-04 | — | — | US | disclosed |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2013-02-28 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110054023-A1 | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses | DUKE UNIVERSITY (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2040699-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | Vanderbilt University Medical Center (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20070297984-A1 | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses | DUKE UNIVERSITY (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | CHRM1 4174/4885KDM4E 4585/4885PARP1 2959/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | CHRM1 3673/4885KDM4E 4440/4885PARP1 3625/4885 |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | CHRM1 4174/4885KDM4E 4585/4885PARP1 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.